|1|Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. (25274443)
Morges M.A.... Thamm D.H.
|2|Novel therapies for cutaneous T-cell lymphoma: what does the future hold? (24397291)
Guenova E.... Cozzio A.
|3|Romidepsin for cutaneous T-cell lymphoma. (24295412)
Prince H.M.... Khot A.
|4|Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma. (24001451)
Suga H.... Sato S.
|5|Expression of miR-155 and miR-126 in situ in cutaneous T-cell lymphoma. (24033365)
Kopp K.L.... Ralfkiaer E.
|6|Canine inflamed nonepitheliotropic cutaneous T-cell lymphoma: a diagnostic conundrum. (23331699)
Moore P.F.... Keller S.M.
|7|Association of nerve growth factor, chemokine (C-C motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma. (22948508)
Suga H.... Sato S.
|8|Comparison of pegylated interferon I+-2b plus psoralen PUVA versus standard interferon I+-2a plus PUVA in patients with cutaneous T-cell lymphoma. (22168776)
HA1sken A.C.... Schiller M.
|9|Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. (22459529)
Frye R.... Booher S.
|10|Integrated positron-emission tomography and computed tomography manifestations of cutaneous T-cell lymphoma. (23247490)
Kamstrup M.R.... Friberg L.
|11|Low herpesvirus entry mediator (HVEM) expression on dermal fibroblasts contributes to a Th2-dominant microenvironment in advanced cutaneous T-cell lymphoma. (22297640)
Miyagaki T.... Sato S.
|12|Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. (22457602)
Li J.Y.... Querfeld C.
|13|Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. (22383798)
Cedeno-Laurent F.... Dimitroff C.J.
|14|Photopheresis in the treatment of cutaneous T-cell lymphoma: current status. (22157241)
|15|The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. (22367792)
Kelly-Sell M.J.... Rook A.H.
|16|IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. (22048239)
Miyagaki T.... Sato S.
|17|Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-I^: implications for therapy of cutaneous T-cell lymphoma. (21942329)
Wysocka M.... Rook A.H.
|18|Romidepsin in the treatment of cutaneous T-cell lymphoma. (22287862)
Jain S.... Zain J.
|19|The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. (22236880)
Abraham R.M.... Wasik M.A.
|20|Absence of TCR loci chromosomal translocations in cutaneous T-cell lymphomas. (21872828)
Salgado R.... Espinet B.
|21|Matrix metalloproteinase-2 promoter genotype as a marker of cutaneous T-cell lymphoma early stage. (20625418)
Vasku A.... Vasku V.
|22|Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk. (20479299)
Pomerantz R.G.... Geskin L.J.
|23|Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. (20888065)
Kim Y.H.... Rook A.H.
|24|Primary cutaneous T-cell lymphoma following organ transplantation in a 16-year-old boy. (19250431)
Amin A.... Morrell D.S.
|25|Primary cutaneous T-cell lymphoma of unspecified type with cytotoxic phenotype: clinicopathological analysis of 27 patients. (19018763)
Hagiwara M.... Nakamura S.
|26|Extracorporeal methoxsalen: new drug. Cutaneous T cell lymphoma: for rare patients, but better assessment needed. (19388212) |2009|
|27|Inhibition of constitutively activated nuclear factor-kappaB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma. (19258503)
Kiessling M.K.... GA1low K.
|28|SAczary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. (18033314)
Booken N.... Goerdt S.
|29|U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. (18241274)
Scarisbrick J.J.... Marshall S.
|30|Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents. (18245554)
Sors A.... Michel L.
|31|T-cell receptor-gamma gene analysis in evolving to advancing cutaneous T-cell lymphoma. (17680965)
Foo C.C.... Tan S.H.
|33|Treatment of cutaneous T-cell lymphoma with retinoids. (17014481)
Zhang C.... Duvic M.
|34|Activation of neutrophils in cutaneous T-cell lymphoma. (16322281)
Goddard D.S.... Jones D.A.
|35|CCR10 is expressed in cutaneous T-cell lymphoma. (15700309)
Notohamiprodjo M.... von Luettichau I.
|36|Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. (15514008)
Berger C.L.... Edelson R.L.
|37|Serological immunomarkers in cutaneous T cell lymphoma. (15539892)
Hassel J.C.... Dummer R.
|38|CD26 expression on cutaneous infiltrates from patients with cutaneous T-cell lymphoma (CTCL) CD26 in cutaneous T-cell lymphoma patients. (12675243)
Novelli M.... Bernengo M.G.
|39|T cell receptor gamma-chain gene polymerase chain reaction to diagnose central nervous system involvement by cutaneous T cell lymphoma. (11986404)
Taylor R.... Bagg A.
|40|Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. (11675351)
Qin J.Z.... DAPbbeling U.
|41|Functional inhibitory receptors expressed by a cutaneous T cell lymphoma-specific cytolytic clonal T cell population. (11121132)
Bagot M.... Martinvallet D.
|42|Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies. (10877054)
|43|Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells. (9864169)
Qin J.Z.... DAPbbeling U.
|44|Immunophenotyping and gene rearrangement analysis provide additional criteria to differentiate between cutaneous T-cell lymphomas and pseudo-T-cell lymphomas. (9176388)
Bakels V.... Willemze R.
|45|A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. (8668164)
Knaus P.I.... Lodish H.F.
|46|Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas. (9049966)
Sarris A.H.... Duvic M.
|47|Chronic actinic dermatitis. An immunohistochemical study of its T-cell antigenic profile, with comparison to cutaneous T-cell lymphoma. (7802165)
Heller P.... Lim H.W.
|48|Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the SAczary syndrome. (8113839)
Foss F.M.... Sausville E.A.
|49|Cutaneous T-cell lymphoma with porokeratosis-like lesions. (1517498)
Hsu W.T.... Kadin M.E.
|50|Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma. (2258637)
Zachariae H.... Thestrup-Pedersen K.